InMatrico®

Tissue-specific extracellular matrix kits and assays for predictive disease modeling and drug testing


Technology

Tissue-specific decellularized ECMs

Predictive results consistent with those in patients: TissueSpec® dECMs enable physiologically-relevant disease modeling and drug testing in matrico by providing the tissue-specific biochemical and mechanical ECM signals lacking in vitro.

Primary tissues

Primary tissues
Tissues are comprised of cells attached to ECM.

Tissue-specific dECMs

Tissue-specific dECMs
Tissue decellularization (cell removal) yields tissue-specific decellularized ECM (dECM).

TissueSpec® dECM Kits

TissueSpec® dECM Kits
Decellularized ECM (dECM) is processed into dECM coating and hydrogel kits.
Primary tissues are decellularized using proprietary protocols to obtain tissue-specific decellularized ECMs (dECM), which are then processed into quality-controlled, ready-to-use TissueSpec® dECM Coating and Hydrogel Kits.

International Distributors

Created with Raphaël 2.1.0

News

Read more

SEPT. 16, 2024

Xylyx Bio awarded $2.45M NIH SBIR grant from National Institute of Diabetes and Digestive and Kidney Diseases

Read more

JUNE 14, 2024

Xylyx Bio Awarded $2.26M NIH SBIR Grant from National Cancer Institute

Read more
Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Sept. 2, 2021

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Contact us

Get in touch

760 Parkside Avenue
New York, NY 11226

(212) 689-9005

info@xylyxbio.com

Name